Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:55:33 EDT Sun 07 Jun 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:MRNA from 2025-06-06 to 2026-06-05 - 67 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-06-03 08:30U:MRNANews ReleasePlatform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
2026-06-02 07:00U:MRNANews ReleaseModerna to Present at Upcoming Conference in June 2026
2026-06-01 08:00U:MRNANews ReleaseModerna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
2026-06-01 05:00U:MRNANews ReleaseModerna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
2026-05-12 17:05U:MRNANews ReleaseModerna Recognized by TIME as One of the World's Most Impactful Companies
2026-05-12 17:00U:MRNANews ReleaseModerna Recognized by TIME as One of the World's Most Impactful Companies
2026-05-11 08:30U:MRNANews ReleaseCNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
2026-05-06 17:16U:MRNANews ReleaseModerna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
2026-05-01 06:30U:MRNANews ReleaseModerna Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-04-21 19:01U:MRNANews ReleaseModerna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
2026-04-21 10:00U:MRNANews ReleaseModerna Announces Data to be Presented at 2026 ASCO Annual Meeting
2026-04-21 09:41U:MRNANews ReleaseModerna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
2026-04-21 07:00U:MRNANews ReleaseModerna to Present at Upcoming Conferences in May 2026
2026-04-17 15:00U:MRNANews ReleaseModerna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
2026-04-15 07:00U:MRNANews ReleaseModerna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
2026-04-06 18:01U:MRNANews ReleaseModerna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
2026-03-03 16:15U:MRNANews ReleaseModerna Resolves Global Patent Litigation with Arbutus/Genevant
2026-02-27 07:00U:MRNANews ReleaseEuropean Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
2026-02-23 16:01U:MRNANews ReleaseTectonic Therapeutic Appoints Francois Nader, M.D., as Chair and Independent Director of the Board
2026-02-19 07:00U:MRNANews ReleaseModerna to Present at Upcoming Conferences in March 2026
2026-02-18 07:00U:MRNANews ReleaseModerna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
2026-02-17 07:00U:MRNANews ReleaseModerna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
2026-02-13 07:00U:MRNANews ReleaseModerna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
2026-02-10 18:00U:MRNANews ReleaseModerna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
2026-02-10 07:00U:MRNANews ReleaseModerna to Enter into Long-Term Strategic Agreement with the Government of Mexico
2026-02-05 09:26U:MRNANews ReleaseThe $71 Billion Cancer Shift: Why The FDA Is Speeding Up
2026-02-04 09:15U:MRNANews ReleaseDefiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.
2026-01-30 07:30U:MRNANews ReleaseDr. David Berman to Join Moderna as Chief Development Officer
2026-01-29 17:00U:MRNANews ReleaseModerna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
2026-01-26 07:00U:MRNANews ReleaseModerna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026
2026-01-20 06:00U:MRNANews ReleaseModerna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following
2026-01-12 07:00U:MRNANews ReleaseModerna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
2026-01-05 07:00U:MRNANews ReleaseModerna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
2025-12-18 07:00U:MRNANews ReleaseCEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate
2025-12-17 07:00U:MRNANews ReleaseModerna to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-15 07:00U:MRNANews ReleaseEMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
2025-12-12 10:47U:MRNANews ReleasePancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
2025-12-12 10:47U:MRNANews ReleasePancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
2025-12-09 09:25U:MRNANews ReleaseGlobal AI Infrastructure Shift Ignites Biotech Growth Phase
2025-11-20 07:00U:MRNANews ReleaseModerna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
2025-11-20 07:00U:MRNANews ReleaseModerna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
2025-11-19 07:00U:MRNANews ReleaseModerna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities
2025-11-18 07:00U:MRNANews ReleaseModerna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025
2025-11-06 07:00U:MRNANews ReleaseModerna Reports Third Quarter 2025 Financial Results and Provides Business Updates
2025-11-03 07:00U:MRNANews ReleaseModerna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma
2025-10-23 14:43U:MRNANews ReleaseModerna Named a Top Employer by Science for Eleventh Consecutive Year
2025-10-23 07:00U:MRNANews ReleaseModerna to Host Investor Event - Analyst Day
2025-10-22 16:05U:MRNANews ReleaseModerna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
2025-10-19 08:00U:MRNANews ReleaseModerna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
2025-10-16 07:00U:MRNANews ReleaseModerna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
2025-10-12 18:05U:MRNANews ReleaseModerna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress
2025-09-24 19:11U:MRNANews ReleaseModerna Opens State-of-the-Art Manufacturing and R&D Facility in the UK
2025-09-23 07:11U:MRNANews ReleaseModerna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
2025-09-19 15:21U:MRNANews ReleaseModerna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
2025-09-16 06:11U:MRNANews ReleaseModerna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
2025-09-02 07:06U:MRNANews ReleaseModerna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
2025-08-27 14:01U:MRNANews ReleaseModerna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
2025-08-22 09:26U:MRNANews ReleaseModerna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
2025-08-21 07:11U:MRNANews ReleaseModerna to Present at Upcoming Conferences in September 2025
2025-08-01 07:12U:MRNANews ReleaseModerna Reports Second Quarter 2025 Financial Results and Provides Business Updates
2025-08-01 06:11U:MRNANews ReleaseUK Court of Appeal Confirms Moderna's EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
2025-07-30 16:11U:MRNANews ReleaseModerna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
2025-07-28 07:11U:MRNANews ReleaseModerna Announces Data to be Presented at ESMO Congress 2025
2025-07-25 08:51U:MRNANews ReleaseEMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
2025-06-30 07:00U:MRNANews ReleaseModerna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
2025-06-12 19:26U:MRNANews ReleaseModerna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18-59 at Increased Risk for RSV Disease
2025-06-11 07:00U:MRNANews ReleaseModerna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025